Evaxion Biotech is committed to the discovery and development of immunotherapies against cancer and infectious diseases
Since 2008, Evaxion has been redefining medicine, pioneering the discovery of neo-epitopes and antigens. We have constructed a robust product engine for the development of novel immunotherapies based on our two platforms, PIONEER and EDEN. Using state-of-the-art in silico tools, the platforms integrate biological data, artificial intelligence and supercomputing to rapidly predict, rank and optimize epitopes and antigens that elicit a highly protective immune response against cancer and infectious diseases.
Our office is situated in central Copenhagen and the heart of Medicon Valley, one of Europe’s largest international life-sciences cluster. With a primary focus on drug discovery and early drug development, we are building on a simple and scalable business model with manageable risk. Currently, Evaxion is collaborating with prominent human and veterinary vaccine companies, labs, and academic and governmental institutions in both Denmark and Boston, U.S., and has notably gained support from the Defense Advanced Research Project Agency (DARPA).